文献速递间质性肺疾病

尼达尼布治疗进展性纤维化性间质性肺疾病的潜力

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
PubMed 文献 · Eur Respir J · 2019-09-19

部分纤维化性间质性肺疾病(ILD)患者会发展为以肺功能下降、生活质量恶化和早期死亡为特征的进展性表型;除特发性肺纤维化(IPF)外,尚无获批药物。尼达尼布已获批治疗IPF,近期显示可减缓系统性硬化症相关ILD(SSc-ILD)患者的肺功能下降速率;体外和动物研究提示其抑制肺纤维化基本过程,INBUILD试验将于2019年报告结果。

要点

  • 尼达尼布已获批治疗IPF,并显示减缓SSc-ILD患者肺功能下降。
  • 除IPF外,纤维化性ILD缺乏获批药物和有力证据支持现有治疗。
  • 尼达尼布在多种纤维化ILD动物模型中显示抗纤维化活性。

核心结论

  • 尼达尼布可能对进展性纤维化性ILD具有治疗潜力,但需等待INBUILD试验结果。

研究设计与样本

  • 综述性文章,总结体外、动物模型及临床试验证据,并提及正在进行的INBUILD试验。

主要发现

  • 尼达尼布减少SSc-ILD患者肺功能下降速率。
  • 体外数据显示尼达尼布抑制促炎和促纤维化介质释放、纤维细胞和成纤维细胞迁移与分化、细胞外基质沉积。
  • 动物模型显示尼达尼布对IPF、SSc-ILD、类风湿关节炎-ILD、过敏性肺炎和矽肺具有抗纤维化活性。

关键数值与推荐

  • 尼达尼布已获批用于治疗IPF。
  • 尼达尼布近期显示可减缓SSc-ILD患者肺功能下降速率。
  • INBUILD试验评估尼达尼布在非IPF进展性纤维化性ILD患者中的效果,将于2019年报告结果。

临床怎么用

  • 尼达尼布可作为IPF和SSc-ILD的治疗选择。
  • 对于其他进展性纤维化性ILD,目前尚无获批药物,临床决策需个体化并等待新证据。

局限性

  • 除IPF外,纤维化性ILD缺乏获批药物和有力证据支持当前治疗。
  • INBUILD试验结果尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive phenotype characterised by decline in lung function, worsening quality of life and early mortality. Other than idiopathic pulmonary fibrosis (IPF), there are no approved drugs for fibrosing ILDs and a poor evidence base to support current treatments. Fibrosing ILDs with a progressive phenotype show commonalities in clinical behaviour and in the pathogenic mechanisms that drive disease worsening. Nintedanib is an intracellular inhibitor of tyrosine kinases that has been approved for treatment of IPF and has recently been shown to reduce the rate of lung function decline in patients with ILD associated with systemic sclerosis (SSc-ILD). In vitro data demonstrate that nintedanib inhibits several steps in the initiation and progression of lung fibrosis, including the release of pro-inflammatory and pro-fibrotic mediators, migration and differentiation of fibrocytes and fibroblasts, and deposition of extracellular matrix. Nintedanib also inhibits the proliferation of vascular cells. Studies in animal models with features of fibrosing ILDs such as IPF, SSc-ILD, rheumatoid arthritis-ILD, hypersensitivity pneumonitis and silicosis demonstrate that nintedanib has anti-fibrotic activity irrespective of the trigger for the lung pathology. This suggests that nintedanib inhibits fundamental processes in the pathogenesis of fibrosis. A trial of nintedanib in patients with progressive fibrosing ILDs other than IPF (INBUILD) will report results in 2019.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019. PMID: 31285305. doi:10.1183/13993003.00161-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。